Compare TBLA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | FTRE |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | 2000 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2023 |
| Metric | TBLA | FTRE |
|---|---|---|
| Price | $4.95 | $19.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.00 | ★ $14.06 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $5.25 | $3.09 |
| P/E Ratio | $42.36 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $2.84 | $5.27 |
| 52 Week High | $5.71 | $20.19 |
| Indicator | TBLA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 72.87 |
| Support Level | $3.94 | $9.10 |
| Resistance Level | $5.18 | N/A |
| Average True Range (ATR) | 0.18 | 0.75 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 24.46 | 81.16 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.